| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCG5 |
| Uniprot No | P05408 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-212aa |
| 氨基酸序列 | MYSPRTPDRV SEADIQRLLH GVMEQLGIAR PRVEYPAHQA MNLVGPQSIE GGAHEGLQHL GPFGNIPNIV AELTGDNIPK DFSEDQGYPD PPNPCPVGKT ADDGCLENTP DTAEFSREFQ LHQHLSDPEH DYPGLGKWNK KLLYEKMKGG ERRKRRSVNP YLQGQRLDNV VAKKSVPHFS DEDKDPE LEH HHHHH |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCG5重组蛋白的3篇参考文献概览(文献标题、作者及摘要内容总结)：
1. **标题**: *Secretogranin V promotes tumor progression via EGF/EGFR signaling in pancreatic cancer*
**作者**: Zhang Y, et al.
**摘要**: 研究探讨了SCG5重组蛋白在胰腺癌中的作用，发现其通过激活EGF/EGFR信号通路促进肿瘤细胞增殖和迁移，提示其作为潜在治疗靶点的价值。
2. **标题**: *Recombinant Secretogranin V (SCG5) modulates neuroendocrine secretion in vitro*
**作者**: Kim H, Lee S.
**摘要**: 利用大肠杆菌表达系统制备SCG5重组蛋白，发现其可调节神经内分泌细胞中激素分泌，揭示了SCG5在神经内分泌系统中的调控机制。
3. **标题**: *SCG5 as a novel biomarker for early-stage colorectal cancer detection*
**作者**: Wang X, et al.
**摘要**: 通过重组SCG5蛋白的血清学分析，证明其在结直肠癌患者早期血清中显著高表达，提示其可能作为非侵入性诊断标志物。
(注：以上文献为示例，实际引用需根据具体研究检索PubMed/Google Scholar获取原文。)
**Background of SCG5 Recombinant Protein**
Secretogranin V (SCG5), also known as 7B2. is a member of the granin family of secretory proteins predominantly localized in neuroendocrine and endocrine cells. It plays a critical role in regulating secretory pathways, particularly through its interaction with prohormone convertases (PCs), enzymes responsible for processing prohormones into bioactive peptides. SCG5 is synthesized as a precursor protein that undergoes proteolytic cleavage to generate a neuropeptide-like fragment and a chaperone-like C-terminal region. The latter is essential for the activation and stabilization of PC2. a key enzyme in neuropeptide biosynthesis.
SCG5 has garnered attention for its dual role in both physiological and pathological contexts. It is implicated in maintaining cellular homeostasis, hormone secretion, and neuronal differentiation. Dysregulation of SCG5 expression has been associated with diseases such as cancer, neurodegenerative disorders, and endocrine tumors. For instance, elevated SCG5 levels are observed in certain cancers, suggesting its potential as a biomarker or therapeutic target.
Recombinant SCG5 protein is engineered using expression systems like *E. coli* or mammalian cell lines to ensure proper folding and post-translational modifications. This allows researchers to study its structural and functional properties, including its interaction with PC2. involvement in secretory granule biogenesis, and role in disease mechanisms. Additionally, recombinant SCG5 serves as a valuable tool in drug discovery, enabling the development of inhibitors or modulators targeting SCG5-associated pathways.
Overall, SCG5 recombinant protein provides a versatile platform for exploring neuroendocrine biology, disease mechanisms, and therapeutic interventions, bridging molecular insights with clinical applications.
×
